US 12,391,662 B2
Lipid compounds and lipid nanoparticle compositions
Shan Cen, Suzhou (CN); Kai Lv, Suzhou (CN); Zhenlei Yu, Suzhou (CN); and Yijie Dong, Suzhou (CN)
Assigned to RINUAGENE BIOTECHNOLOGY CO. LTD., (CN); and RINUAGENE INTERNATIONAL HK LIMITED, (CN)
Filed by RINUAGENE BIOTECHNOLOGY CO., LTD., Suzhou (CN); and RINUAGENE INTERNATIONAL HK LIMITED, Kowloon (CN)
Filed on May 28, 2024, as Appl. No. 18/675,317.
Application 18/675,317 is a continuation of application No. PCT/CN2023/142449, filed on Dec. 27, 2023.
Claims priority of application No. PCT/CN2022/143065 (WO), filed on Dec. 28, 2022; application No. PCT/CN2023/124515 (WO), filed on Oct. 13, 2023; and application No. 202311790946.8 (CN), filed on Dec. 25, 2023.
Prior Publication US 2024/0343701 A1, Oct. 17, 2024
Prior Publication US 2025/0145582 A2, May 8, 2025
Int. Cl. C07D 317/12 (2006.01); A61K 9/51 (2006.01); A61K 45/06 (2006.01); C07D 319/06 (2006.01); C07D 327/04 (2006.01); C07D 339/06 (2006.01)
CPC C07D 317/12 (2013.01) [A61K 9/5123 (2013.01); A61K 45/06 (2013.01); C07D 319/06 (2013.01); C07D 327/04 (2013.01); C07D 339/06 (2013.01)] 20 Claims
 
1. A compound of formula (I), or a salt or a stereoisomer thereof,

OG Complex Work Unit Chemistry
wherein
R1 is

OG Complex Work Unit Chemistry
R1a and R1b are each independently —CH3;
R2 and R3 are each independently H;
R4 is C10, C11 or C12 linear alkyl;
R5 and R6 are identical and are selected from C6, C7 and C8 linear alkyl;
X and Y are each independently O;
X1 and X2 are independently selected from C═O and O, Y1 and Y2 are independently selected from C═O and O, with the proviso that X1 and Y1 are not both C═O or O, and X2 and Y2 are not both C═O or O;
m is 0, and n is 1;
o is 5 or 6;
p is 7 or 8, and
q is 2, 3 or 4.